Clinical relevance of CYP2D6 genotype on β-blocker treatment. Poor CYP2D6 metabolizers experience a greater reduction in heart rate (a) and a higher risk of bradycardia when treated with metoprolol.
HR = heart rate; PM = poor metabolizer.
Reprinted with permission from Macmillan Publishers Ltd.: [Clinical Pharmacology & Therapeutics] Rau T et al., Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study 2009; 85: 269–72.